reports
D`ieteren Group: 2 directors
Two Directors at D`ieteren Group bought 4,500 shares at between 162.611EUR and 165.970EUR. The significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over ...
- ING Helpdesk
Benelux Morning Notes
Azelis: Highlights ING Benelux Conference London. Barco: Highlights ING Benelux Conference London. Kinepolis: Highlights ING Benelux Conference London. Melexis: Highlights ING Benelux Conference London. ABN AMRO: Dutch State reducing stake to 20%. ASML: x Mistral, a bet on A.I.. Kinepolis: Cineplex August 2025 box office revenue at 87% of 2019 level, down 27% YoY
- Guy Sips
- Livio Luyten
- Thibault Leneeuw
- Guy Sips
Kinepolis Group Keep The Faith, they Wanna Be Startin' Somethin' in M&...
Investors should Keep The Faith as Kinepolis Group showed resilience in 1H25, rebounding from a weak start with strong 2Q visitor growth and rising profitability, supported by premium formats. While the delay of the Michael biopic (originally planed for 3Q) deprived cinemas of a potential blockbuster boost, Kinepolis' management remains confident. Despite a challenging August and an uncertain 3Q outlook, a strong 4Q and FY26 pipeline offers hope for recovery. In the meantime, Kinepolis continues...
- Michiel Declercq
D'Ieteren No room for error in 2H25, with Belron in focus
1H25 results disappointed with the adj. PBT (gs) down 22.7% to € 452.4m (kbcse: € 493m, css: € 475m). Note that on a comparable basis, the adj. PBT (gs) only decreased by 8.7%, but remained below the full year guidance (slight improvement). The miss was driven by a weak performance at TVH Parts, and only modest margin improvement at Belron. While the reiteration of the FY25 outlook implies a big step up in Belron's margins in 2H25, we give the group the benefit of the doubt. This because manage...
- ING Helpdesk
- Hilde Van Boxstael
- Lynn Hautekeete
- Michiel Declercq
- Guy Sips
- Hilde Van Boxstael
- Kristof Samoy
- Livio Luyten
- Michiel Declercq
- Thibault Leneeuw
- Wim Hoste
- Wim Lewi
Dynamic Top Pick List Update September: Adding AB InBev and Exor
In this September update we added 2 stocks to the KBC Securities Dynamic Top Pick List : We added AB InBev after the share price weakened post-2Q results. ABI's 2Q volumes fell 1.9% organically, below expectations, mainly due to a 9% drop in Brazil where a price hike led to temporary market share loss. However, strong revenue per hl growth (+4.9%) drove a 6.5% organic EBITDA increase, with 1H growth at +7.2%, near the top of FY guidance (+4–8%). AB InBev, the world's largest brewer, generates ...
- Michiel Declercq
D'Ieteren 1H25: Soft results, but reiterated outlook implies large ste...
1H25 results disappointed, with the adj. PBT (gs) down 22.7% to € 452.4m (kbcse: € 493m, css: € 475m). On a comparable basis, the adj. PBT (gs) only decreased by 8.4%, falling short of the “slight improvement” guided for FY25. The miss was driven by soft results at TVH Parts and only modest margin improvement at Belron. While the reiteration of the FY25 outlook implies a big step up in Belron's margins in 2H25, we give the group the benefit of the doubt. This because management highlighted durin...
- ING Helpdesk
- David Vagman
- CFA
Kinepolis/More popcorn, more EBITDA/BUY
We up our EPS up 2%-1%, our target price remains unchanged. Kinepolis reported a strong 1H, on better operating leverage, higher ticket and ITS, slightly higher visitors while net debt was in line. We slightly cut our visitors estimates on a more prudent 3Q, but this is more than offset by higher spend per visitor and margins. The stock underperforms 22% YTD, as a too-bullish consensus was adjusting to a weaker attendance. We think the case is worth revisiting. The pure standalone recovery story...
- ING Helpdesk
- Dominic Rose
- Naresh Chouhan
UCB - Quantifying the MoonLake Risk
UCB is our highest conviction BUY despite the imminent HS Phase 3 readout from MoonLake. We show the NPV downside is likely MSD, that ~40% of Bim sales are unaffected by sonelokimab & that UCB will out-muscle MoonLake across many domains. Our analysis of the HS data shows that background antibiotic use will need to be considered & that the drugs look very similar. However, UCB’s ~$5bn rebate wall, the >€1bn higher M&S spend than Moonlake & the L-T safety data all protect Bim’, as will the psoria...
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Lynn Hautekeete
- Michiel Declercq
- Thomas Couvreur
- Wim Hoste
- Jacob Mekhael
UCB PREVIEW: Upcoming phase 3 data from Bimzelx competitor in HS
Upcoming phase 3 data from Bimzelx competitor, sonelokimab (IL17A/F nanobody), in HS is expected in September. In this note, we preview the readout and outline a few potential scenarios, highlighting the potential upside/downside for UCB's stock. While the stock may take a hit if sonelokimab shows a numerical difference on the primary endpoint, this will depend on the extent of the delta, and we see more limited downside if the numerical difference is on the smaller end, particularly in the cont...
- Michiel Declercq
D'Ieteren 1H25 Preview
On September 3rd, D'Ieteren's will report its 1H25 results after market close. In our estimates, we expect the adj. PBT (gs) to decline 15.8% on a reported basis to € 493m (css: € 475m). Note however that we expect this decline to be fully driven by refinancing as our estimates still assume a 1.1% increase in adj. EBIT (gs). As usual, the highlight of the results will be the performance at Belron. Contrary to the traditional seasonality, we expect margin improvement at Belron to be weighed towar...
UCB SA: 1 director
A director at UCB SA bought 143 shares at 199.570EUR and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing ...
- Jacob Mekhael
UCB To present on epilepsy portfolio at the International Epilepsy Con...
UCB will present 26 abstracts from its epilepsy portfolio at the International Epilepsy Congress (IEC) in Lisbon, being held 30 August – 3 September. As well as qualitative and caregiver studies, the presentations will include a combined open label extension study of 412 DS and LGS patients who took part in Fintepla (fenfluramine) studies, and shows no new or unexpected safety signals with long-term sustained benefit, which we view as supportive of Fintepla's benefit in this patient population. ...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Livio Luyten
- Lynn Hautekeete
- Wim Hoste
- Wim Lewi
- Guy Sips
Biotalys EPA's review on Evoca in 4Q rather than by end September
In an update on the regulatory approval procedure in the US of Evoca, its first protein-based biocontrol product, Biotalys has received further guidance from EPA, the U.S. Environmental Protection Agency on the regulatory review of Evoca. The EPA has confirmed that the scientific review of the dossier is progressing, and that all the requests for additional information have been addressed. While the agency continues to work diligently on the review, Biotalys now expects the final steps of the re...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.